Cantor Fitzgerald Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price

Eli Lilly and Company (NYSE:LLY) had its price objective upped by equities research analysts at Cantor Fitzgerald from $1,410.00 to $1,440.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 21.32% from the stock’s current price.

Other equities analysts have also recently issued reports about the company. Leerink Partners increased their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a research note on Wednesday. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Truist Financial raised their price target on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Berenberg Bank set a $1,400.00 target price on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,313.43.

Eli Lilly and Company Stock Up 2.5%

LLY stock opened at $1,186.95 on Thursday. The firm has a market cap of $1.12 trillion, a PE ratio of 39.83, a PEG ratio of 1.42 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The firm’s 50 day moving average price is $1,173.51 and its 200-day moving average price is $1,094.59. Eli Lilly and Company has a one year low of $783.85 and a one year high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 36.66 EPS for the current year.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald Zakrowski sold 2,000 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by company insiders.

Institutional Trading of Eli Lilly and Company

Institutional investors and hedge funds have recently bought and sold shares of the stock. Osbon Capital Management LLC acquired a new stake in Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Basso Capital Management L.P. acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $30,000. Maseco LLP increased its stake in shares of Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after buying an additional 28 shares during the period. Aventus Investment Advisors Inc. boosted its stake in shares of Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after purchasing an additional 27 shares during the last quarter. Finally, Marshall & Sterling Wealth Advisors Inc. increased its holdings in Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after purchasing an additional 15 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Jim Cramer said he would favor Lilly over Novo Nordisk for a three- to five-year investment horizon, calling Lilly a high-quality company. The endorsement reinforces bullish sentiment around Lilly’s long-term growth prospects. Jim Cramer’s comparison of Novo Nordisk and Eli Lilly
• Positive Sentiment: Investors are increasingly looking beyond current blockbusters to retatrutide, Lilly’s next-generation triple-hormone obesity treatment. Reported trial weight loss has exceeded Zepbound’s results, and a potential FDA filing in early 2027 provides a major future catalyst. Lilly’s retatrutide drug data
• Positive Sentiment: Recent coverage highlights additional growth opportunities in oncology, immunology, neuroscience, and an oral GLP-1 candidate, Foundayo. Lilly also reported favorable Foundayo data versus oral semaglutide, potentially strengthening its competitive position in diabetes and obesity care. Foundayo clinical data
• Neutral Sentiment: Analysts remain divided: Lilly’s rapid revenue growth and pipeline support a premium valuation, but the stock trades near 40 times trailing earnings, leaving limited room for execution disappointments. Lilly’s growth and valuation analysis
• Negative Sentiment: New World Health Organization childhood-obesity guidelines could increase scrutiny of pediatric obesity treatments and create additional regulatory or market-access challenges for Lilly and Novo Nordisk. WHO childhood-obesity guidelines

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.